Thermo Fisher Scientific Inc. announced the enrollment of the first patient in the new PPD?? CorEvitas?? Myasthenia Gravis (MG) Registry.
This nationwide registry will collect data from MG patients across the United States to study and evaluate existing and emerging MG therapies, tracking health conditions, safety issues, medication usage and overall treatment effectiveness. By leveraging real-world data, the registry will enhance understanding of MG and improve patient care. MG is a rare autoimmune disorder of the neuromuscular junction causing muscle weakness and fatigue that worsens with activity and may fluctuate daily.
While more common in adults, MG can affect people of all ages, and the exact cause is unknown. It is estimated that over 70,000 people in the U.S. have been diagnosed with MG. Patients can experience a wide range of symptoms that can vary from mild to severe and may include periods of removal with no symptoms, severe episodes that worsen with daily activities, or myasthenic crisis, which involves severe muscle weakness affecting breathing or swallowing, requiring medical support such as intubation or ventilation.
There's currently no way to prevent or cure MG, but treatment can help manage symptoms. The registry is designed to collect clinical data from enrolled patients under the care of a neurologist in both academic and private practice settings. The registry is now active in the U.S., with the first patient enrolled on November 10. This registry was launched under the scientific guidance of James Howard, M.D., professor of neurology, medicine and allied health, University of North Carolina at Chapel Hill; and Michael Benatar, M.D., Ph.D., professor of neurologY and public health sciences, University of Miami Health System.
This is the 14th independent registry from PPD?? CorEvita?? Clinical Registries, part of the PPD clinical research business of Thermo Fisher Scientific.
CorEvitas Clinical Registries solutions include proprietary autoimmune and inflammatory disease registries containing structured, regulatory-grade patient clinical data spanning more than 500 investigator sites and over 100,000 patients followed longitudinally. The CorEvitas Clinical Registries independent registry model has been accepted by regulators for long-term post-authorization safety studies across a variety of disease indications.
